drugset
drugset / Trial / NCT01398956

An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures

NCT01398956 ↗

Phase 3 Completed 44 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

The investigators will provide Levetiracetam treatment to epilepsy subjects in Japan who are judged to benefit from continued treatment with Levetiracetam by the investigators and who are willing to continuously receive this drug.

Timeline

Start
2011-06
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 20 mg/kg Oral
Subject Levetiracetam Other / unclassified 40 mg/kg Oral
Subject Levetiracetam Other / unclassified 60 mg/kg Oral
Subject Levetiracetam Other / unclassified 1000 mg Oral
Subject Levetiracetam Other / unclassified 2000 mg Oral
Subject Levetiracetam Other / unclassified 3000 mg Oral

Indications

epilepsy with generalized tonic-clonic seizures